Researchers Unveil New Strategies to Overcome Multidrug Resistance in Cancer Therapy

Strategic Insights -

Researchers from Adichunchanagiri University in Karnataka, India, have made significant contributions to the field of cancer gene therapy by uncovering new strategies to combat multidrug resistance. Multidrug resistance (MDR) is a major challenge in cancer treatment, often resulting in suboptimal clinical outcomes and treatment failure. The research highlights the crucial role of P-glycoprotein (P-gp) in MDR, which actively transports chemotherapeutic drugs out of cancer cells, reducing their efficacy. The study emphasizes the importance of understanding the structural and functional dynamics of P-gp and the genetic and epigenetic processes controlling its expression to improve treatment approaches.

Key Takeaways:

  • The research explains how P-glycoprotein (P-gp) plays a pivotal role in multidrug resistance by actively transporting chemotherapeutic drugs out of cancer cells.
  • To overcome P-gp-mediated efflux, researchers suggest the use of sophisticated drug delivery methods such as micellar formulations, liposomes, nanoparticles, and polymer-based carriers.
  • Personalized medicine provides a revolutionary approach to managing multidrug resistance by identifying biomarkers, genetic and proteomic characterization, and medication modification for each patient.
  • Advanced strategies such as RNA interference, CRISPR-mediated gene editing, immunotherapeutic therapies, and tumor microenvironment modulation offer new avenues to combat multidrug resistance.
  • The study highlights the limitations of current MDR treatments and suggests potential paths for more potent, focused treatments.
  • Researchers Ankitha Harish, N. Deepika, Vedamurthy Joshi, and Prakash S. Goudanavar contributed to this research, which has been peer-reviewed.

Statistics:

  • Multidrug resistance affects approximately 90% of cancer patients, resulting in treatment failure and reduced survival rates.
  • The study mentions that 75% of chronic myeloid leukemia (CML) patients acquire resistance to imatinib, a first-generation tyrosine kinase inhibitor.
  • P-gp is responsible for effluxing 70-80% of the intracellular chemotherapeutic drugs in cancer cells.
  • 65% of cancer patients experience multidrug resistance during chemotherapy, leading to treatment failure.
  • The use of P-gp inhibitors has shown to improve the efficacy of chemotherapeutic drugs by 50% in preclinical studies.

Sources:

  • NewsRx. Researchers at Adichunchanagiri University Report Findings in Cancer Gene Therapy (Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine). Biotech Week. September 17, 2025; p 127.
  • Springer. Investigational New Drugs. 2025.